Amorphous substance and crystal of dioxopiperidine compound or pharmaceutically acceptable salt thereof, preparation method, and use

By developing the amorphous form and pharmaceutically acceptable salt crystal form of compound I, the PROTAC mechanism was used to achieve highly efficient ubiquitination and degradation of androgen receptors, solving the problems of drug resistance and toxic side effects of existing AR inhibitors and providing a more effective treatment option for prostate cancer.

WO2024240246A1PCT designated stage expired Publication Date: 2024-11-28JIANGSU HENGRUI MEDICINE CO LTD +1

Patent Information

Application Number
PCT/CN2024/095156
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing AR inhibitors are prone to developing resistance when treating prostate cancer, and traditional small molecule inhibitors require long-term, high-intensity binding, leading to toxic side effects and failing to effectively regulate the ubiquitination and degradation of androgen receptor proteins.

Method used

Amorphous forms of Formula I compounds and various pharmaceutically usable salt crystals were developed. By binding to androgen receptor proteins, efficient and sustained protein degradation was achieved using the PROTAC mechanism. This included the preparation of amorphous forms and crystals of different pharmaceutically usable salts, such as succinate and mandelate, and crystallization using specific solvent and antisolvent systems.

Benefits of technology

It achieves efficient ubiquitination and degradation of androgen receptors, reduces drug exposure, lowers toxic side effects, prolongs the drug's half-life in vivo, and has significant pharmacokinetic advantages, making it suitable for treating androgen receptor-mediated diseases such as prostate cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024095156_28112024_PF_FP_ABST
    Figure CN2024095156_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to an amorphous substance and a crystal of a dioxopiperidine compound or a pharmaceutically acceptable salt thereof, a preparation method, and a use. Specifically, the present disclosure relates to an amorphous substance and a crystal of a compound shown in formula I or a pharmaceutically acceptable salt thereof, which have good physical and chemical properties.
Need to check novelty before this filing date? Find Prior Art

Description

Amorphous substance, crystal, preparation method and use of dioxopiperidine compound or pharmaceutically acceptable salt thereof

[0001] This application claims priority to Chinese patent application No. 2023105921952, filed May 24, 2023. This application incorporates the entirety of the aforementioned Chinese patent application. Technical Field

[0002] The present disclosure belongs to the field of medicine and relates to an amorphous substance, crystal, preparation method and use of a dioxopiperidine compound or a pharmaceutically acceptable salt thereof. Background Art

[0003] PROTAC (PROteolysis Targeting Chimera) is a hybrid bifunctional small molecule compound. Its structure contains two different ligands: one is the ubiquitin ligase E3 ligand, and the other is the target protein binding ligand, and the two ligands are connected by a linker unit. PROTAC forms a target protein-PROTAC-E3 ternary complex by bringing the target protein and the ubiquitin ligase E3 in the cell closer. The E3 ubiquitin ligase then tags the target protein with a ubiquitinated protein tag, and then activates the powerful ubiquitination-proteasome system in the cell to specifically degrade the target protein, thereby inhibiting the corresponding protein signaling pathway (Cell Biochem Funct. 2019, 37, 21-30). Compared with traditional small molecule inhibitors, PROTACs exhibit unique advantages: 1) PROTACs do not require long-term and high-intensity binding to the target protein, and the process of degrading the target protein is similar to a catalytic reaction. They can cyclically bind to and degrade the target protein, thereby reducing the systemic exposure of the drug and reducing the occurrence of toxic side effects; 2) After being degraded, the target protein needs to be resynthesized to restore its function. Therefore, degrading the target protein shows a more efficient and lasting anti-tumor effect than inhibiting its activity, and there will be no drug resistance caused by target protein mutations; 3) PROTACs also have therapeutic potential for targets that are currently considered undruggable, such as transcription factors, scaffold proteins, and regulatory proteins.

[0004] The discovery of CRBN-type E3 ligase ligands was closely related to the study of thalidomide's mechanism of action. In 2010, while investigating thalidomide toxicity, scientists discovered cereblon as a thalidomide-binding protein (Science 2010, 327, 1345). Cerebellum is part of the E3 ubiquitin ligase protein complex, acting as a substrate receptor to selectively target ubiquitinated proteins. This study suggested that thalidomide-cereblon binding in vivo may contribute to thalidomide's teratogenicity. Subsequent studies have shown that this compound and related structures may be useful as anti-inflammatory, anti-angiogenic, and anticancer agents. Further modifications of the thalidomide structure have yielded lenalidomide and pomalidomide, which have significantly improved safety and reduced teratogenicity. Lenalidomide was approved by the FDA in 2006. Two groundbreaking papers published in Science in 2014 indicated that lenalidomide exerts its effects by degrading two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3). This further revealed that thalidomide may further play a role in degrading target proteins by binding to the E3 ubiquitin ligase protein complex of cerebellum (Science, 2014, 343, 301; Science, 2014, 343, 305).

[0005] The androgen receptor (AR) is a ligand-dependent, transactivating transcriptional regulatory protein belonging to the nuclear receptor superfamily, primarily located in the cell nucleus. Unliganded AR binds to heat shock protein (HSP). Upon ligand binding, AR undergoes a conformational change, dissociating from HSP and increasing its affinity for DNA (AR activation). Activated AR binds as a dimer to a specific DNA sequence in the cell nucleus—the androgen response element (ARE)—and interacts with other transcription factors, thereby regulating the expression of related genes and producing biological effects. Studies have shown that abnormalities in the AR signaling pathway are closely associated with the development and progression of diseases such as prostate cancer, benign prostatic hyperplasia, Kennedy's disease, male infertility, androgen insensitivity, and male breast cancer.

[0006] Prostate cancer is one of the most common malignant tumors. According to statistics, in 2018, there were nearly 1.3 million new cases and 359,000 deaths worldwide, accounting for 13.5% of the incidence of male malignant tumors, ranking second, and 6.7% of the mortality rate of male malignant tumors, ranking fifth. Several AR antagonists have been approved for marketing and successfully used to treat castration-resistant prostate cancer, becoming the mainstay of prostate cancer treatment. However, most patients develop drug resistance after 0.5-2 years of treatment, leading to disease progression. In some resistant patients, cancer cell growth still depends on the AR signaling pathway.

[0007] PCT / CN2022 / 134333 provides a class of compound structures for regulating ubiquitination and degradation of androgen receptor (AR) proteins, whose chemical name is 2-chloro-4-((S)-8-(4-(4-((4-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)-2-fluorophenyl)-3-methyl-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile, having the structure shown in Formula I. The entire text is incorporated herein by reference.

[0008] Summary of the Invention

[0009] In a first aspect, the present disclosure provides an amorphous form of the compound represented by Formula I.

[0010] In some embodiments, the amorphous form of the compound represented by Formula I has an X-ray powder diffraction pattern without sharp peaks, preferably with non-sharp peaks, and more preferably, an X-ray powder diffraction pattern as shown in FIG1 .

[0011] In some embodiments, the amorphous form of the compound represented by Formula I has a DSC spectrum showing an endothermic peak value of 122.02±3°C.

[0012] In some embodiments, the amorphous form of the compound of Formula I has a thermogravimetric analysis (TGA) spectrum showing a weight loss of about 5.06% at 33-170°C.

[0013] The present disclosure also provides a method for preparing an amorphous form of the compound of Formula I, comprising: mixing the compound of Formula I with solvent A, and crystallizing to obtain an amorphous form. In some embodiments, the solvent A is selected from one or more of water, methanol, ethanol, isopropanol, n-propanol, isoamyl alcohol, isopropyl acetate, methyl tert-butyl ether, n-heptane, cyclohexane, and toluene.

[0014] The present disclosure also provides a method for preparing an amorphous form of the compound of Formula I, comprising: mixing the compound of Formula I with a solvent B, adding an anti-solvent, and crystallizing to obtain an amorphous form. In some embodiments, the solvent B is selected from one or more of dimethyl sulfoxide, acetone, acetonitrile, tetrahydrofuran, and dichloromethane; and the anti-solvent is selected from one or more of water, ethanol, n-heptane, or isopropyl ether.

[0015] In a second aspect, the present disclosure further provides a pharmaceutically acceptable salt of the compound of Formula I, wherein the pharmaceutically acceptable salt is selected from succinate, mandelate, oxalate, phosphate, hydrochloride, maleate, fumarate, hydrobromide, citrate, sulfate, methanesulfonate, hippurate, benzoate, malate, and acetate; preferably succinate and mandelate; more preferably succinate and D-mandelate.

[0016] In some embodiments, the chemical ratio of the compound represented by formula I to the acid molecule or acid radical is 2:0.5 to 1:3; preferably, the chemical ratio of the compound represented by formula I to the acid molecule or acid radical is selected from 2:1 to 1:3; more preferably, the chemical ratio of the compound represented by formula I to the acid molecule or acid radical is selected from 1:0.5, 1:1, 1:1.5 or 1:2.

[0017] The present disclosure also provides a succinate salt crystal form A of the compound represented by Formula I, wherein the X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 6.170, 11.215, 12.380, 15.558, 18.230, and 18.884.

[0018] In some embodiments, the succinate salt form A of the compound represented by Formula I has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, and has characteristic peaks at 6.170, 9.506, 11.215, 12.380, 15.558, 18.230, 18.884, 19.429, 21.392, and 23.609.

[0019] In some embodiments, the X-ray powder diffraction pattern of the succinate salt form A of the compound represented by Formula I, expressed in terms of a diffraction angle 2θ, is shown in FIG2 .

[0020] In some embodiments, the succinate salt form A of the compound represented by Formula I, wherein the chemical ratio of the compound of Formula I to succinate or succinic acid is about 1:1 to 1:2, preferably 1:1 or 1:2.

[0021] In some embodiments, the succinate salt crystal form A of the compound represented by Formula I has a DSC spectrum showing an endothermic peak value of 97.22±3°C.

[0022] The present disclosure also provides a succinate salt crystal form B of the compound represented by Formula I, wherein the X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 6.402, 9.400, 15.728, 17.957, and 19.070.

[0023] In some embodiments, the succinate salt form B of the compound represented by Formula I has characteristic peaks at 6.402, 9.400, 15.728, 17.957, 19.070, and 21.589.

[0024] In some embodiments, the X-ray powder diffraction pattern of the succinate salt form B of the compound represented by Formula I, expressed in terms of a diffraction angle 2θ, is shown in FIG3 .

[0025] In some embodiments, the succinate salt form B of the compound represented by Formula I has a DSC spectrum showing an endothermic peak value of 121.36±3°C.

[0026] In some embodiments, the succinate salt form B of the compound represented by Formula I, wherein the chemical ratio of the compound of Formula I to succinate or succinic acid is about 1:1 to 1:2, preferably 1:1 or 1:2.

[0027] The present disclosure also provides a succinate salt crystal form C of the compound represented by Formula I, wherein the X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 5.555, 5.588, 9.363, 11.165, 18.229, and 18.668.

[0028] In some embodiments, the succinate salt form C of the compound represented by Formula I has characteristic peaks at 5.555, 5.588, 9.363, 11.165, 15.505, 18.229, 18.668, 19.734, and 21.920.

[0029] In some embodiments, the succinate salt form C of the compound represented by Formula I has characteristic peaks at 5.555, 5.588, 9.363, 11.165, 15.505, 18.229, 18.668, 19.734, 21.920, and 26.943.

[0030] In some embodiments, the X-ray powder diffraction pattern of the succinate salt form C of the compound represented by Formula I, expressed in terms of a diffraction angle 2θ, is shown in FIG4 .

[0031] In some embodiments, the succinate salt crystal form C of the compound represented by Formula I has a DSC spectrum showing endothermic peak values ​​of 93.71±3°C and 118.69±3°C.

[0032] In some embodiments, the succinate salt form C of the compound represented by Formula I, wherein the chemical ratio of the compound of Formula I to succinate or succinic acid is about 1:1 to 1:2, preferably 1:1 or 1:2.

[0033] The present disclosure provides a method for preparing the above-mentioned succinate salt crystal form C, which comprises: mixing the compound represented by Formula I with tetrahydrofuran and succinic acid, and crystallizing to obtain the succinate salt crystal form C.

[0034] The present disclosure also provides a succinate salt crystal form D of the compound represented by Formula I, wherein the X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 6.878, 10.856, 11.784, 18.225, and 18.597.

[0035] In some embodiments, the succinate salt form D of the compound represented by Formula I has characteristic peaks at 6.878, 10.856, 11.784, 15.639, 17.314, 18.225, 18.597, 19.103, 19.755, 20.155, and 21.477.

[0036] In some embodiments, the succinate salt form D of the compound represented by Formula I has characteristic peaks at 6.878, 10.856, 11.784, 15.639, 17.314, 18.225, 18.597, 19.103, 19.755, 20.155, 21.477, and 27.367.

[0037] In some embodiments, the succinate salt form D of the compound represented by Formula I has characteristic peaks at 6.878, 10.856, 11.784, 15.639, 17.314, 18.225, 18.597, 19.103, 19.755, 20.155, 21.477, 22.268, 24.672, 25.655, 27.367, 28.023, and 28.715.

[0038] In some embodiments, the X-ray powder diffraction pattern of the succinate salt form D of the compound represented by Formula I, expressed in terms of a diffraction angle of 2θ, is shown in FIG5 .

[0039] In some embodiments, the succinate salt of the compound represented by Formula I is in crystal form D, and the DSC spectrum of the crystal form shows an endothermic peak value of 132.93±3°C.

[0040] In some embodiments, the succinate salt form D of the compound represented by Formula I, wherein the chemical ratio of the compound of Formula I to succinate or succinic acid is about 1:1 to 1:2, preferably 1:1 or 1:2.

[0041] The present disclosure provides a method for preparing the above-mentioned succinate salt crystal form D, which comprises: mixing the compound represented by formula I with acetone and succinic acid, and crystallizing at low temperature to obtain the succinate salt crystal form D.

[0042] The present disclosure provides a D-mandelate salt A crystalline form of the compound represented by Formula I, wherein the X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 10.554, 13.168, 15.728, 17.944, and 19.784.

[0043] In some embodiments, the D-mandelate salt form A of the compound represented by Formula I has characteristic peaks at 6.159, 8.371, 10.554, 13.168, 15.728, 17.944, 19.784, and 20.381.

[0044] In some embodiments, the D-mandelate salt form A of the compound of Formula I has characteristic peaks at 6.159, 8.371, 10.554, 13.168, 15.728, 17.944, 19.784, 20.381, 21.121, and 21.434.

[0045] More preferably, the X-ray powder diffraction pattern represented by the diffraction angle 2θ is as shown in FIG6 .

[0046] In some embodiments, the D-mandelate salt of the compound represented by Formula I is in crystal form A, and the DSC spectrum of the crystal form shows an endothermic peak value of 176.10±3°C.

[0047] In some embodiments, the D-mandelate salt form A of the compound of Formula I, wherein the chemical ratio of the compound of Formula I to mandelate or mandelic acid is about 1:1.

[0048] The present disclosure also provides a method for preparing the D-mandelate salt crystal form A of the compound represented by Formula I, comprising: mixing the compound represented by Formula I with a solvent and D-mandelic acid, and crystallizing to obtain the D-mandelate salt crystal form A; the solvent is selected from one or more of isopropanol, ethanol, and ethyl acetate, and preferably the solvent is selected from isopropanol / ethyl acetate, ethanol / ethyl acetate, and ethyl acetate.

[0049] The present disclosure provides an oxalate salt I crystal form of a compound represented by formula I, wherein the X-ray powder diffraction pattern represented by a diffraction angle 2θ has characteristic peaks at 4.885, 11.219, 12.092, 14.565, 16.383, and 18.201.

[0050] More preferably, the X-ray powder diffraction pattern represented by the diffraction angle 2θ is as shown in FIG7 .

[0051] In some embodiments, the oxalate salt form I of the compound represented by Formula I has an endothermic peak value of 136.67±3° C. as shown in the DSC spectrum of the crystalline form.

[0052] In some embodiments, the oxalate salt form I of the compound represented by Formula I, wherein the chemical ratio of the compound of Formula I to oxalate or oxalic acid is about 1:1 to 1:3, preferably 1:1 or 1:2.

[0053] The present disclosure also provides a method for preparing the oxalate I crystal form of the compound represented by Formula I, which comprises: mixing the compound represented by Formula I with acetonitrile and oxalic acid, and crystallizing to obtain the oxalate I crystal form.

[0054] The present disclosure provides a hydrochloride salt crystalline form I of a compound represented by formula I, wherein an X-ray powder diffraction pattern represented by a diffraction angle 2θ has characteristic peaks at 4.891, 11.255, 16.565, 17.947, and 22.056.

[0055] More preferably, the X-ray powder diffraction pattern represented by the diffraction angle 2θ is as shown in FIG9 .

[0056] In some embodiments, the hydrochloride salt form I of the compound represented by Formula I has a DSC spectrum showing an endothermic peak value of 194.65±3°C.

[0057] In some embodiments, the hydrochloride salt form I of the compound represented by Formula I, wherein the chemical ratio of the compound of Formula I to chloride ion or hydrogen chloride is about 2:1 to 1:3, preferably 1:1 or 1:2.

[0058] The present disclosure also provides a method for preparing hydrochloric acid of the compound represented by Formula I, which comprises: mixing the compound represented by Formula I with acetonitrile and hydrochloric acid, and crystallizing to obtain hydrochloride salt form I.

[0059] The present disclosure also provides an amorphous form of the phosphate of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG8 .

[0060] The present disclosure also provides an amorphous maleate of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG10 .

[0061] The present disclosure also provides an amorphous fumarate of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is shown in FIG11 .

[0062] The present disclosure also provides an amorphous form of the hydrobromide salt of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG12 .

[0063] The present disclosure also provides an amorphous form of a citrate salt of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG13 .

[0064] The present disclosure also provides an amorphous sulfate of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG14 .

[0065] The present disclosure also provides an amorphous form of a methanesulfonate salt of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG15 .

[0066] The present disclosure also provides an amorphous form of hippurate of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG16 .

[0067] The present disclosure also provides an amorphous form of a benzoate salt of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG17 .

[0068] The present disclosure also provides an amorphous form of a malate salt of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG18 .

[0069] The present disclosure also provides an amorphous form of the acetate salt of the compound represented by Formula I, whose X-ray powder diffraction pattern has no sharp peaks, preferably has non-sharp peaks, and more preferably, its X-ray powder diffraction pattern is as shown in FIG19 .

[0070] The crystallization method described in the present disclosure is conventional, such as volatilization crystallization, cooling crystallization, beating crystallization, room temperature crystallization, and stirring crystallization.

[0071] The present disclosure also provides a pharmaceutical composition, which comprises the above-mentioned amorphous form, pharmaceutically acceptable salt, crystal form or crystal form prepared by the above-mentioned preparation method, and optionally a pharmaceutically acceptable excipient.

[0072] The present disclosure also provides a method for preparing a pharmaceutical composition, comprising the step of mixing the above-mentioned amorphous substance, pharmaceutically acceptable salt, crystalline form or the crystalline form prepared by the above-mentioned preparation method with a pharmaceutically acceptable excipient.

[0073] The present disclosure also provides a use of the above-mentioned amorphous substance, pharmaceutically acceptable salt, crystalline form, crystalline form prepared by the above-mentioned preparation method, or the above-mentioned pharmaceutical composition in the preparation of a drug for regulating ubiquitination and degradation of androgen receptor (AR) protein.

[0074] The present disclosure also provides a use of the above-mentioned amorphous substance, pharmaceutically acceptable salt, crystal form, crystal form prepared by the above-mentioned preparation method or the above-mentioned pharmaceutical composition for regulating ubiquitination and degradation of androgen receptor (AR) protein.

[0075] The present disclosure also provides the above-mentioned amorphous substance, pharmaceutically acceptable salt, crystal form, crystal form prepared by the above-mentioned preparation method or the above-mentioned pharmaceutical composition for regulating ubiquitination and degradation of androgen receptor (AR) protein.

[0076] The present disclosure also provides use of the above-mentioned amorphous form, pharmaceutically acceptable salt, crystalline form, crystalline form prepared by the above-mentioned preparation method, or the above-mentioned pharmaceutical composition in the preparation of a medicament for treating and / or preventing a disease or condition mediated by or dependent on the androgen receptor; wherein the disease or condition mediated by or dependent on the androgen receptor is preferably selected from tumors, male sexual dysfunction, and Kennedy's disease.

[0077] The present disclosure also provides a use of the above-mentioned amorphous form, pharmaceutically acceptable salt, crystalline form, crystalline form prepared by the above-mentioned preparation method, or the above-mentioned pharmaceutical composition for treating and / or preventing diseases or conditions mediated by or dependent on androgen receptors; wherein the diseases or conditions mediated by or dependent on androgen receptors are preferably selected from tumors, male sexual dysfunction, and Kennedy's disease.

[0078] The present disclosure also provides the above-mentioned amorphous form, pharmaceutically acceptable salt, crystalline form, crystalline form prepared by the above-mentioned preparation method, or pharmaceutical composition for treating and / or preventing diseases or conditions mediated or dependent on androgen receptors, wherein the diseases or conditions mediated or dependent on androgen receptors are preferably selected from tumors, male sexual dysfunction, and Kennedy's disease.

[0079] In some embodiments, the androgen receptor-mediated or -dependent disease or condition is selected from prostate cancer, prostatic hyperplasia, hirsutism, alopecia, anorexia nervosa, breast cancer, acne, male sexual dysfunction, Kennedy's disease and AIDS, preferably prostate cancer, more preferably hormone-sensitive prostate cancer or hormone-refractory prostate cancer.

[0080] The "2θ or 2θ angle" mentioned in the present disclosure refers to the diffraction angle, θ is the Bragg angle, and the unit is ° or degree; the error range of each characteristic peak 2θ is ±0.2 (including the case where the number exceeding 1 decimal place is rounded off), which can be -0.20, -0.19, -0.18, -0.17, -0.16, -0.15, -0.14, -0.13, -0.12, -0.11, -0.10, -0.09, - 0.08, -0.07, -0.06, -0.05, -0.04, -0.03, -0.02, -0.01, 0.00, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20.

[0081] According to the description of hygroscopic characteristics and the definition of hygroscopic weight gain in the "9103 Guiding Principles for Hygroscopicity of Drugs" in Part IV of the 2015 edition of the Chinese Pharmacopoeia,

[0082] Deliquescent: Absorbs sufficient water to form a liquid;

[0083] Highly hygroscopic: weight gain due to moisture absorption is not less than 15%;

[0084] Hygroscopic: weight gain due to moisture absorption is less than 15% but not less than 2%;

[0085] Slightly hygroscopic: weight gain due to moisture absorption is less than 2% but not less than 0.2%;

[0086] No or almost no hygroscopicity: weight gain due to moisture is less than 0.2%.

[0087] The "differential scanning calorimetry or DSC" described in this disclosure refers to measuring the temperature difference and heat flow difference between a sample and a reference object during the process of heating or maintaining the sample at a constant temperature to characterize all physical and chemical changes related to thermal effects and obtain phase change information of the sample.

[0088] The drying temperature in the present disclosure is generally 25°C to 100°C, preferably 40°C to 70°C. Drying can be performed at normal pressure or reduced pressure, with a pressure of less than -0.08 MPa.

[0089] The "excipients" described in this disclosure include, but are not limited to, any adjuvant, carrier, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent or emulsifier that has been approved by the U.S. Food and Drug Administration for use by humans or livestock animals.

[0090] The "beating" mentioned in the present disclosure refers to a purification method that utilizes the property that a substance has poor solubility in a solvent but impurities have good solubility in a solvent. Beating purification can remove color, change the crystal form or remove a small amount of impurities.

[0091] The starting material used in the crystal form preparation method of the present invention can be any form of compound, including but not limited to: amorphous matter, any crystal form, hydrate, solvate, etc.

[0092] Numerical values ​​in this disclosure, such as those related to substance content, are derived from measurements and calculations, and therefore inevitably have a certain degree of error. Generally speaking, ±10% is considered within a reasonable error range. While there may be some degree of error depending on the context in which they are used, this error may not exceed ±10% and may include ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1%, preferably ±5%.

[0093] The compound of formula I disclosed herein, 2-chloro-4-((S)-8-(4-(4-((4-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)-2-fluorophenyl)-3-methyl-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile (hereinafter referred to as compound I) was prepared by referring to the method in PCT / CN2022 / 134333, and the relevant content is quoted in this text for illustration. BRIEF DESCRIPTION OF THE DRAWINGS

[0094] FIG1 is an XPRD spectrum of the amorphous compound of formula I.

[0095] Figure 2 is an XPRD spectrum of Form A succinate salt of Formula I.

[0096] Figure 3 is an XPRD spectrum of Form B succinate of Formula I.

[0097] Figure 4 is an XPRD spectrum of Form C succinate of Formula I.

[0098] Figure 5 is an XPRD spectrum of Form D succinate salt of Formula I.

[0099] FIG6 is an XPRD spectrum of Form A of the mandelate salt of Formula I.

[0100] FIG7 is an XPRD spectrum of Form I oxalate salt.

[0101] FIG8 is an XPRD spectrum of an amorphous phosphate of Formula I.

[0102] Figure 9 is an XPRD spectrum of Form I hydrochloride.

[0103] FIG10 is an XPRD spectrum of the maleate amorphous form of Formula I.

[0104] FIG11 is an XPRD spectrum of the amorphous fumarate of Formula I.

[0105] FIG12 is an XPRD spectrum of the amorphous hydrobromide of Formula I.

[0106] FIG13 is an XPRD spectrum of amorphous citrate of Formula I.

[0107] FIG14 is an XPRD spectrum of amorphous citrate of Formula I.

[0108] FIG15 is an XPRD spectrum of the amorphous form of the methanesulfonate of Formula I.

[0109] FIG16 is an XPRD spectrum of the hippurate amorphous form of Formula I.

[0110] FIG17 is an XPRD spectrum of an amorphous form of the benzoate salt of Formula I.

[0111] FIG18 is an XPRD spectrum of an amorphous form of the malate salt of Formula I.

[0112] FIG19 is an XPRD spectrum of the acetate amorphous form of Formula I. DETAILED DESCRIPTION

[0113] The present disclosure is further described below with reference to the following embodiments, but these embodiments are not intended to limit the scope of the present disclosure.

[0114] Example

[0115] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). -6 The unit of ppm is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer or a Bruker AVANCE NEO 500M NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), or deuterated methanol (CD3OD), and tetramethylsilane (TMS) was used as the internal standard.

[0116] MS was measured using an Agilent 1200 / 1290 DAD-6110 / 6120 Quadrupole MS liquid spectrometer-mass spectrometer (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS).

[0117] waters ACQuity UPLC-QD / SQD (Manufacturer: waters, MS model: waters ACQuity Qda Detector / waters SQ Detector)

[0118] THERMO Ultimate 3000-Q Exactive (Manufacturer: THERMO, MS model: THERMO QExactive)

[0119] High performance liquid chromatography (HPLC) analysis was performed using Agilent HPLC 1200DAD, Agilent HPLC 1200VWD and Waters HPLC e2695-2489 high performance liquid chromatographs.

[0120] Chiral HPLC analysis was performed using an Agilent 1260DAD high performance liquid chromatograph.

[0121] High performance liquid chromatography (HPLC) was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP, and Gilson GX-281 preparative chromatographs.

[0122] Chiral preparations were performed using a Shimadzu LC-20AP preparative chromatograph.

[0123] The CombiFlash rapid preparation instrument used was Combiflash Rf200 (TELEDYNE ISCO).

[0124] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The specification of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm~0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm~0.5mm.

[0125] Silica gel column chromatography generally uses Yantai Huanghai 200-300 mesh silica gel as the carrier.

[0126] Average kinase inhibition rate and IC 50 The values ​​were determined using a NovoStar microplate reader (BMG, Germany).

[0127] The known starting materials disclosed herein can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Darui Chemicals, and other companies.

[0128] Unless otherwise specified in the examples, all reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.

[0129] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1 L.

[0130] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.

[0131] The pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.

[0132] The hydrogenation reaction is usually carried out by evacuating the chamber and filling it with hydrogen, and the operation is repeated three times.

[0133] A CEM Discover-S 908860 microwave reactor was used for the microwave reaction.

[0134] Unless otherwise specified in the examples, the solution refers to an aqueous solution.

[0135] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.

[0136] The reaction progress in the examples was monitored by thin layer chromatography (TLC). The developing solvents used in the reactions, the eluent systems for column chromatography and the developing solvent systems for thin layer chromatography used to purify the compounds included: A: dichloromethane / methanol system, B: n-hexane / ethyl acetate system. The volume ratio of the solvents was adjusted according to the polarity of the compounds, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.

[0137] XRPD is X-ray powder diffraction detection: the measurement was carried out using a BRUKER D8 X-ray diffractometer, and the specific collection information was: Cu anode (40kV, 40mA), Cu-Kα1 ray Kα2 rays Kβ rays Scanning range (2θ range): 3 to 45°.

[0138] DSC is differential scanning calorimetry: the measurement was performed using a METTLER TOLEDO DSC 3+ differential scanning calorimeter with a heating rate of 10°C / min. The specific temperature range was referred to the corresponding spectrum (mostly 25-300 or 25-350°C), and a nitrogen purge rate of 50 mL / min.

[0139] TGA is thermogravimetric analysis: the test was performed using a METTLER TOLEDO TGA 2 thermogravimetric analyzer with a heating rate of 10°C / min. The specific temperature range refers to the corresponding spectrum (mostly 30-350°C), and a nitrogen purge rate of 50 mL / min.

[0140] DVS stands for dynamic moisture sorption: the test uses SMSDVS Advantage. At 25°C, the humidity changes from 50% to 95% to 0% to 95% to 50%, with a step of 10% (the last step is 5%) (the specific humidity range is subject to the corresponding spectrum, and the method listed here is mostly used). The judgment criteria are Tmax ≤ 360min and dm / dt no more than 0.002%.

[0141] Ion Chromatography: Instrument: American DIONEX AQUION Ion Chromatograph, Detection Method: Conductivity; Separation Column: IonPac AS14A-AG14; Eluent: NaHCO 3 0.5 mM + Na 2 CO 3 4.0 mM; Flow Rate: 1.0 mL / min. Example 1 The compound represented by Formula I was synthesized using the preparation method of Example 15-1 in patent application PCT / CN2022 / 134333.

[0142] 2-Chloro-4-((S)-8-(4-(4-((4-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)-2-fluorophenyl)-3-methyl-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile 1-1 (Formula I)

[0143] 2-Chloro-4-((S)-8-(4-(4-((4-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)-2-fluorophenyl)-3-methyl-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile 1-2

[0144] first step

[0145] (±)-tert-Butyl 4-((4-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperazin-1-yl)methyl)piperidine-1-carboxylate 1b

[0146] To a 25 mL three-necked flask was added 3 mL of a mixed solution of dichloromethane and methanol (V / V=2 / 1), and (±)-3-((3-(piperazin-1-yl)phenyl)amino)piperidine-2,6-dione 1a (90 mg, 0.25 mmol, prepared by the method disclosed in "Compound 86 on page 266 of the specification of patent application WO 2018237026A1"), anhydrous sodium acetate (102 mg, 1.24 mmol), and the mixture was reacted for 15 minutes. Tert-butyl 4-formylpiperidine-1-carboxylate (85 mg, 0.40 mmol) was added and the reaction was continued for 30 minutes. Sodium triacetoxyborohydride (106 mg, 0.50 mmol) was slowly added and the reaction was continued for 16 hours. Under ice cooling, 10 mL of saturated sodium bicarbonate solution was added to the system to quench the reaction. The mixture was extracted with dichloromethane (20 mL × 3). The organic phases were combined and washed with saturated sodium chloride solution (20 mL × 3). The organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent System B to give the title compound 1b (110 mg, yield: 90%).

[0147] MS m / z(ESI):486.6[M+1].

[0148] Step 2

[0149] (±)-3-((3-(4-(piperidin-4-ylmethyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione dihydrochloride 1c

[0150] Compound 1b (105 mg, 0.22 mmol) was dissolved in 3 mL of dichloromethane. A 4M solution of hydrogen chloride in 1,4-dioxane (0.53 mL) was slowly added under an ice bath and allowed to react for 4 hours. The reaction mixture was concentrated and dried under vacuum to afford the crude title compound 1c (99 mg, 98% yield), which was used directly in the next reaction without purification.

[0151] MS m / z(ESI):386.5[M+1].

[0152] Step 3

[0153] 2-Chloro-4-((3S)-8-(4-(4-((4-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)-2-fluorophenyl)-3-methyl-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile 1 (diastereoisomer mixture)

[0154] To a 25 mL three-necked flask were added 2 mL of N,N-dimethylformamide, compound 1c (50 mg, 0.094 mmol), (S)-4-(2-(3-chloro-4-cyanophenyl)-3-methyl-2,8-diazaspiro[4.5]dec-8-yl)-3-fluorobenzoic acid 1d (45 mg, 0.083 mmol, prepared by the method disclosed in Example 52 on page 271 of the specification of patent application "WO2021055756A1"), and N,N-diisopropylethylamine (85 mg, 0.66 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (63 mg, 0.16 mmol) were slowly added under ice bath. The cooling bath was removed and the reaction was carried out for 16 hours. The reaction solution was filtered and purified by high performance liquid chromatography (Waters 2545, elution system: 10 mmol / L ammonium bicarbonate in water and acetonitrile, acetonitrile gradient: 50%-95%, flow rate: 30 mL / min) to give the title compound 1 (diastereoisomer mixture, ratio 1:1, 36 mg, yield: 54%).

[0155] MS m / z(ESI):795.3[M+1];

[0156] 1 H NMR (500MHz, DMSO-d6): δ10.75(s,1H),7.59(d,1H),7.13(d,1H),7.11(s,1H),7.06(t,1H),6.89(t,1H),6 .79(d,1H),6.65(dd,1H),6.24(s,1H),6.17(d,1H),6.12(d,1H),5.60(d,1H),4.35-4.25(m,1H),4.07-3.9 7(m,1H),3.43(d,1H),3.34-3.30(m,3H),3.17-2.92(m,8H),2.78-2.68(m,1H),2.64-2.50(m,3H),2.48-2 .40(m,4H),2.28-1.93(m,4H),1.90-1.67(m,5H),1.62-1.48(m,3H),1.27-1.15(m,4H),1.12-0.99(m,2H).

[0157] Step 4

[0158] 2-Chloro-4-((S)-8-(4-(4-((4-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)-2-fluorophenyl)-3-methyl-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile 1-1 (Formula I)

[0159] 2-Chloro-4-((S)-8-(4-(4-((4-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)-2-fluorophenyl)-3-methyl-2,8-diazaspiro[4.5]dec-2-yl)benzonitrile 1-2

[0160] Compound 1 (21 mg) was subjected to chiral preparative separation (separation conditions: Gilson-281, chromatographic column: Phenomenex Amylose-2, 5um, 21.2mm*250mm, mobile phase: acetonitrile (0.5% 7M ammonia (NH3) methanol solution) / ethanol (0.5% 7M ammonia (NH3) methanol solution) = 40 / 60 (v / v)), flow rate 20 mL / min) to obtain the title compound 1-2 (5 mg) and compound 1-1 (8 mg), respectively.

[0161] 1-2 (5 mg, yield: 24%), shorter retention time:

[0162] MS m / z(ESI):795.3[M+1].

[0163] Chiral HPLC analysis method: retention time 3.53 minutes (Agilent 1260 DAD, column: Phenomenex LUX Amylose-2, (4.6×150 mM), 5 μm; mobile phase: acetonitrile / ethanol / diethylamine = 40 / 60 / 0.06 (v / v / v), flow rate 1 mL / min);

[0164] 1 H NMR (500MHz, DMSO-d6): δ10.75(s,1H),7.59(d,1H),7.14(d,1H),7.12(s,1H),7.06(t,1H),6.90(t,1H),6 .79(d,1H),6.65(dd,1H),6.24(s,1H),6.17(d,1H),6.13(d,1H),5.61(d,1H),4.35-4.25(m,1H),4.07-3.9 7(m,1H),3.43(d,1H),3.37-3.30(m,3H),3.17-2.92(m,8H),2.78-2.68(m,1H),2.64-2.50(m,3H),2.48-2 .40(m,4H),2.28-1.93(m,4H),1.90-1.67(m,5H),1.62-1.48(m,3H),1.27-1.15(m,4H),1.12-0.99(m,2H).

[0165] Compound 1-1 (8 mg, yield: 38%), longer retention time:

[0166] MS m / z(ESI):795.3[M+1].

[0167] Chiral HPLC analysis method: retention time 4.19 minutes (Agilent 1260 DAD, column: Phenomenex LUX Amylose-2, (4.6×150 mM), 5 μm; mobile phase: acetonitrile / ethanol / diethylamine = 40 / 60 / 0.06 (v / v / v), flow rate 1 mL / min);

[0168] 1 H NMR (500MHz, DMSO-d6): δ10.76(s,1H),7.59(d,1H),7.13(d,1H),7.11(s,1H),7.06(t,1H),6.90(t,1H),6 .80(d,1H),6.65(dd,1H),6.24(s,1H),6.17(d,1H),6.12(d,1H),5.61(d,1H),4.35-4.25(m,1H),4.07-3.9 7(m,1H),3.43(d,1H),3.34-3.30(m,3H),3.17-2.92(m,8H),2.78-2.68(m,1H),2.64-2.50(m,3H),2.48-2 .40(m,4H),2.28-1.93(m,4H),1.90-1.67(m,5H),1.62-1.48(m,3H),1.27-1.15(m,4H),1.12-0.99(m,2H).

[0169] Biological evaluation

[0170] The present disclosure is further described and explained below in conjunction with test examples, but these test examples are not intended to limit the scope of the present disclosure.

[0171] Test Example 1: Determination of the degradation activity of the disclosed compounds on androgen receptor in LNCaP cells

[0172] The in vitro cell assay described below can determine the degradation activity of the test compound on the androgen receptor (AR) in human prostate cancer cell lines. The activity can be measured by DC 50On the first day of the experiment, LNCaP cells (ATCC, CRL-1740) were seeded at a density of 20,000 cells / well in 96-well plates using phenol red-free RPMI 1640 medium (Gibco, 11835-030) containing 5% charcoal-stripped fetal bovine serum (Shanghai Bosheng Biotechnology Co., Ltd., S-FBS-AU-045). 200 μL of cell suspension was added to each well and the cells were incubated at 37°C, 5% CO2 for three days. On the fourth day, 22 μL of a serial dilution of the test compound prepared in plating medium containing 1 nM R1881 (Aladdin, M305037) was added to each well. The final concentration of R1881 was 0.1 nM. The compound was diluted six-fold starting from 2.5 μM to a final concentration of seven concentration points. A blank control well containing 0.5% DMSO was set up. The plates were incubated at 37°C, 5% CO2 for 24 hours. On the fifth day, remove the 96-well cell culture plate, aspirate the cell culture supernatant, discard, and wash the cells once with 300 μL of ice-cold PBS. Add 50 μL of 1× lysis buffer (Cell Signaling Technology, #9803S) diluted in ddH2O containing 1 mM PMSF. Shake on a microplate for 1 minute, place the plate on ice for 15-20 minutes, mix thoroughly, and centrifuge at 4000 rpm for 10 minutes at 4°C. AR protein levels were measured using an AR ELISA kit (Cell Signaling Technology, #12850) according to the manufacturer's instructions. Add 96 μL of sample diluent and 4 μL of sample lysis buffer or blank lysis buffer to the 96-well plate. Seal the plate, shake well, and incubate in a 37°C incubator for 2 hours. Discard the remaining liquid, wash the plate five times with 300 μL of wash buffer per well, and then add 100 μL of detection antibody working solution. Seal the plate and incubate in a 37°C incubator for 1 hour. Discard the liquid in the wells, add 300 μL of washing solution to each well, wash the plate five times, then add 100 μL of enzyme conjugate working solution, seal the plate and incubate in a 37°C incubator for 30 minutes. Discard the liquid in the wells, add 300 μL of washing solution to each well, wash the plate five times, then add 100 μL of colorimetric solution, seal the plate and incubate at room temperature in the dark for 5 minutes, and add 100 μL of stop solution to each well. After mixing, immediately place it in a microplate reader (BMG Labtech, PHERAstar FS) to read the OD450 and OD540 values. The OD450 absorbance value in all wells was subtracted from the OD540 absorbance value in the corresponding well to obtain the corrected OD450 absorbance value (OD450-correction). The degradation rate of each concentration of the compound was calculated by the following formula, where the maximum value (Max) is the maximum degradation rate of the compound to degrade AR. GraphPad Prism was used to fit the curve and calculate DC based on the logarithmic concentration and degradation efficiency of the compound. 50Degradation rate (%) = (OD450-calibration 空白对照 -OD450-Calibration 化合物 ) / (OD450-calibration 空白对照 -OD450-Calibration 裂解液对照 )×100%

[0173] The biological activities of the disclosed compounds were determined by the above analysis. The DC 50 and Max values ​​are shown in Table 1 below.

[0174] Table 1 Degradation activity of the disclosed compounds on androgen receptor in LNCaP cells

[0175] Conclusion: The disclosed compounds have significant degradation activity on androgen receptor in LNCaP cells.

[0176] Test Example 2: Determination of the proliferation inhibition of LNCaP by the disclosed compounds

[0177] The following in vitro cell assay can determine the inhibitory activity of the test compound on the proliferation of human prostate cancer cell lines. The activity can be measured by IC 50 On the first day of the experiment, LNCaP cells (ATCC, CRL-1740) were seeded at a density of 7500 cells / well in 96-well plates using phenol red-free RPMI 1640 medium (Gibco, 11835-030) containing 5% charcoal-stripped fetal bovine serum (Shanghai Bosheng Biotechnology Co., Ltd., S-FBS-AU-045). 200 μL of cell suspension was added to each well and the plates were cultured in a 37°C, 5% CO2 cell incubator for three days. On the fourth day, 22 μL of a serial dilution of the test compound prepared in plating medium containing 1 nM R1881 (Aladdin, M305037) was added to each well. The final concentration of R1881 was 0.1 nM. The final concentration of the compound was 9 concentration points of 4-fold serial dilution starting from 10 μM. Blank control wells containing 0.5% DMSO and control wells without cell solvent were set up. The wells were placed in a cell culture incubator at 37°C and 5% CO2 for 6 days. On the tenth day, the 96-well cell culture plate was removed, 110 μL of cell culture supernatant was aspirated and discarded from each well, and then 50 μL of Luminescent Cell Viability Assay (Promega, G7573) was used. After standing at room temperature for 10 minutes, the luminescence signal value (RLU) was read using a multifunctional microplate reader (PerkinElmer, VICTOR 3). The inhibition rate of each concentration of the compound was calculated using the following formula, where the maximum value (Max) is the maximum inhibition rate of the compound in inhibiting proliferation. GraphPad Prism was used to fit the curve based on the logarithmic concentration and inhibition rate of the compound and calculate the IC 50 Inhibition rate (%) = (RLU 空白对照 -RLU 化合物 ) / (RLU 空白对照 -RLU 溶媒对照 )×100%

[0178] The biological activities of the disclosed compounds were determined by the above analysis and the calculated IC 50 The values ​​are shown in Table 2 below.

[0179] Table 2 Inhibitory activity of the disclosed compounds on LNCaP cells

[0180] Conclusion: The disclosed compounds have good proliferation inhibitory activity on LNCaP cells.

[0181] Test Example 3 Pharmacokinetic Evaluation

[0182] Comparative Example 1 (synthesized with reference to patent WO2021055756A1, Example 307) has the following structure:

[0183] ARV-110 (synthesized according to patent WO2018071606A1, Example 406) has the following structure:

[0184] 1. SD rat experiment

[0185] 1. Abstract

[0186] SD rats were used as test animals, and the drug concentrations in plasma at different time points after gavage (ig) of the disclosed compounds were determined by LC / MS / MS to study the pharmacokinetic behavior of the disclosed compounds in SD rats and evaluate their pharmacokinetic characteristics.

[0187] 2. Experimental plan

[0188] 2.1 Investigational Drugs

[0189] The compound of Example 1;

[0190] Example 1-1 compound;

[0191] Comparative Example 1 compound.

[0192] 2.2 Experimental animals

[0193] Twelve SD rats, half male and half female, were divided equally into three groups and provided by Weitonglihua Experimental Animal Co., Ltd. After fasting overnight, the rats were gavage-administered with the drug.

[0194] 2.3 Drug preparation

[0195] A certain amount of the compound to be tested was weighed and added with 5% DMSO + 5% Tween 80 + 90% normal saline to prepare a 0.2 mg / mL clear solution.

[0196] 2.4 Administration

[0197] The dosage was 2.0 mg / kg, and the administration volume was 10.0 mL / kg.

[0198] 3. Operation

[0199] Before dosing and at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 11.0, and 24.0 hours after dosing, collect 0.2 mL of blood from the eye socket and place it in an EDTA-K2 anticoagulant tube. Centrifuge at 10,000 rpm for 1 minute (4°C). Plasma is separated within 1 hour and stored at -20°C until testing. The entire process from blood collection to centrifugation should be performed in an ice bath. Eat 2 hours after dosing.

[0200] Determination of the content of the test compound in the plasma of SD rats after administration of different drug concentrations: 25 μL of SD rat plasma samples at each time point after administration were taken, 200 μL of acetonitrile to precipitate protein and 50 μL of camptothecin (100 ng / mL) were added, vortexed for 5 minutes, and centrifuged at 4000 rpm for 10 minutes. 30 μL of the supernatant was taken, diluted with 120 μL of water, and 1 μL was taken for LC / MS / MS analysis.

[0201] 4. Pharmacokinetic parameter results

[0202] Table 3 Pharmacokinetic parameters of the disclosed compounds in SD rats

[0203] Conclusion: Compared with Comparative Example 1, the disclosed compound has a larger area under the curve in SD rats, a prolonged half-life, a reduced clearance rate, and has good pharmacokinetic absorption activity and obvious pharmacokinetic advantages.

[0204] 2. Dog Test

[0205] 1. Abstract

[0206] Beagle dogs were used as test animals. LC / MS / MS was used to determine the drug concentration in plasma at different time points after gavage (ig) of the disclosed compound to study the pharmacokinetic behavior of the disclosed compound in beagle dogs and evaluate its pharmacokinetic characteristics.

[0207] 2. Experimental plan

[0208] 2.1 Investigational Drugs

[0209] Example 1-1 compound;

[0210] Compound ARV-110.

[0211] 2.2 Experimental animals

[0212] Eight beagle dogs, half male and half female, were divided equally into two groups and were provided by Jiangsu Zhaoshengyuan Biotechnology Co., Ltd. After fasting overnight, the dogs were gavage-administered.

[0213] 2.3 Drug preparation

[0214] A certain amount of the compound to be tested was weighed and added with 5% DMSO + 30% PG + 30% PEG400 + 35% normal saline to prepare a 0.4 mg / mL solution.

[0215] 2.4 Administration

[0216] The dosage was 2.0 mg / kg and the administration volume was 5.0 mL / kg.

[0217] 3. Operation

[0218] Before dosing and at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 11.0, and 24.0 hours after dosing, 0.5 mL of blood was collected from the forelimb vein. The blood was placed in an EDTA-K2 anticoagulant tube and centrifuged at 10,000 rpm for 2 minutes at 4°C. Plasma was separated within 1 hour and stored at -80°C until testing. The blood collection and centrifugation process was performed in an ice bath. Food was consumed 3 hours after dosing.

[0219] Determination of the test compound content in beagle dog plasma after administration of different drug concentrations: 50 μL of beagle dog plasma samples at various times after administration were collected, 25 μL of camptothecin (1 μg / mL) and 450 μL of acetonitrile were added to precipitate protein, the mixture was vortexed, and centrifuged at 3700 rpm for 10 minutes. 0.5 μL of the supernatant was collected for LC / MS / MS analysis.

[0220] 4. Pharmacokinetic parameter results

[0221] Table 4 Pharmacokinetic parameters of the disclosed compounds in beagle dogs

[0222] Conclusion: Compared with compound ARV-110, the disclosed compound has a larger area under the curve in beagle dogs, a lower clearance rate, good pharmacokinetic absorption activity, and obvious pharmacokinetic advantages.

[0223] 3. Monkey Experiment

[0224] 1. Abstract

[0225] Cynomolgus monkeys were used as test animals, and the plasma drug concentrations of the disclosed compounds at different time points after gavage (ig) were determined by LC / MS / MS to study the pharmacokinetic behavior of the disclosed compounds in cynomolgus monkeys and evaluate their pharmacokinetic characteristics.

[0226] 2. Experimental plan

[0227] 2.1 Investigational Drugs

[0228] Example 1-1 compound;

[0229] ARV-110.

[0230] 2.2 Experimental animals

[0231] Eight cynomolgus monkeys, half male and half female, were divided equally into two groups and provided by Medicipia Pharmaceutical Technology (Shanghai) Co., Ltd. After fasting overnight, the monkeys were gavage-administered.

[0232] 2.3 Drug preparation

[0233] A certain amount of the compound to be tested was weighed and added with 5% DMSO + 30% PG + 30% PEG400 + 35% normal saline to prepare a 0.4 mg / mL clear solution.

[0234] 2.4 Administration

[0235] The dosage was 2.0 mg / kg and the administration volume was 5.0 mL / kg.

[0236] 3. Operation

[0237] Before dosing and at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, and 24.0 hours after dosing, 1 mL of blood was collected from the forelimb vein. The blood was placed in an EDTA-K2 anticoagulant tube and centrifuged at 2200 g for 10 minutes (2-8°C). Plasma was separated within 1 hour and stored at -80°C until testing. The blood collection and centrifugation process was performed in an ice bath. Three hours after dosing, the subjects were fed and had free access to water.

[0238] Determination of the content of the test compound in the plasma of cynomolgus monkeys after administration of different drug concentrations: Take 20 μL of cynomolgus monkey plasma samples at each time point after administration, add 400 μL of methanol to precipitate protein (containing 10 ng / mL verapamil), vortex mix for 1 minute, and centrifuge at 18,000 g for 7 minutes. Take 5 μL of the supernatant for LC / MS / MS analysis.

[0239] 4. Pharmacokinetic parameter results

[0240] Table 5 Pharmacokinetic parameters of the disclosed compounds in cynomolgus monkeys are as follows:

[0241] Conclusion: Compared with ARV-110, the disclosed compound has a larger area under the curve and a lower clearance rate in cynomolgus monkeys, has good pharmacokinetic absorption activity, and has obvious pharmacokinetic advantages.

[0242] Example 2 Preparation of free amorphous material

[0243] 10 mg of the compound represented by Formula I was added to 1 mL of solvent A. The sample was stirred and slurried at room temperature, filtered, and the filter cake was collected and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was a free amorphous substance. The XRPD spectrum is shown in Figure 1. The DSC spectrum showed an endothermic peak at 122.02°C. The TGA spectrum showed a weight loss of 5.06% from 33°C to 170°C.

[0244] Table 6

[0245] Example 3 Preparation of free amorphous material

[0246] The compound represented by Formula I was added to solvent B and dissolved, and an antisolvent was added to precipitate the mixture, which was centrifuged and then vacuum dried to obtain a solid. X-ray powder diffraction analysis showed that the product was amorphous.

[0247] Table 7

[0248] Example 4 Preparation of Succinate Crystal Form A

[0249] 10 mg of the compound represented by Formula I was dissolved in 0.3 mL of acetone, and 3.26 mg of solid succinic acid was added and dissolved. The mixture was stirred overnight at room temperature, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis identified the product as crystalline succinate Form A. The XRPD spectrum is shown in Figure 2, and the positions of its characteristic peaks are shown in Table 8. The DSC spectrum showed an endothermic peak at 97.22°C. The TGA spectrum showed a weight loss of 1.51% between 35°C and 71°C, and a weight loss of 7.23% between 71°C and 131°C. Ion chromatography analysis revealed a succinate ion content of 14.8%.

[0250] Table 8

[0251] Example 5 Preparation of Succinate Crystal Form B

[0252] 10 mg of the compound represented by Formula I was dissolved in 0.1 mL of acetone. 1.63 mg of solid succinic acid was added and dissolved. The mixture was stirred overnight at room temperature to precipitate solids, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis identified the product as crystalline succinate Form B. The XRPD spectrum is shown in Figure 3, and the positions of its characteristic peaks are shown in Table 9. The DSC spectrum showed an endothermic peak at 121.36°C. The TGA spectrum showed a weight loss of 2.19% from 36°C to 120°C. Ion chromatography analysis revealed a succinate ion content of 13.2%.

[0253] Table 9

[0254] Example 6 Preparation of Succinate Crystal Form C

[0255] 10 mg of the compound represented by Formula I was dissolved in 0.3 ml of tetrahydrofuran, and 3.26 mg of solid succinic acid was added and dissolved. The mixture was stirred overnight at room temperature to precipitate a solid, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis identified the product as crystalline Form C of the succinate salt. The XRPD spectrum is shown in Figure 4, and the positions of its characteristic peaks are shown in Table 10. The DSC spectrum showed endothermic peaks at 93.71°C and 118.69°C. The TGA spectrum showed a weight loss of 8.96% between 31°C and 131°C. Ion chromatography analysis revealed a succinate ion content of 19.3%.

[0256] Table 10

[0257] Example 7 Preparation of Succinate Crystal Form D

[0258] 10 mg of the compound represented by Formula I was added to 0.3 mL of acetone and dissolved. 1.63 mg of solid succinic acid was added and dissolved. The mixture was stirred overnight at room temperature without precipitation. The mixture was stirred overnight at 5°C to precipitate solids. The mixture was centrifuged and dried under vacuum to obtain a solid. X-ray powder diffraction analysis identified the product as succinate D crystal form. The XRPD spectrum is shown in Figure 5, and the positions of its characteristic peaks are shown in Table 11. The DSC spectrum showed an endothermic peak at 132.93°C. The TGA spectrum showed a weight loss of 1.63% between 36 and 80°C and a weight loss of 4.00% between 80 and 140°C. Ion chromatography analysis showed a succinate ion content of 12.9%.

[0259] Table 11

[0260] Example 8D - Preparation of Mandelate A Crystalline Form

[0261] The compound of Formula I (100 mg, 125.72 mmol) was dissolved in 8 mL of a mixed solvent of isopropanol and ethyl acetate (V / V = 1 / 1). A solution of D-mandelic acid (19.13 mg, 125.72 μmol) in ethyl acetate (0.5 mL) was added and stirred at room temperature for 48 hours. A solid precipitated, and the reaction mixture was filtered, the filter cake collected, and vacuum dried to give the title product (100 g, 84.7% yield).

[0262] 1 H NMR characterization showed that the compound represented by Formula I formed a salt with D-mandelic acid in a 1:1 ratio.

[0263] 1 H NMR(500MHz,DMSO)δ10.76(d,1H),7.64-7.57(m,1H),7.41(t,2H),7.38-7.31(m,2H),7.28(q,1H),7.18-7.11(m,2H),7. 08(d,1H),6.91(s,1H),6.81(d,1H),6.70-6.64(m,1H),6.26(s,1H),6.17(dt,2H),5.62(t,1H),5.02-4.98(m,1H),4.31 (t,1H),4.04(q,1H),3.45(d,1H),3.39-3.34(m,3H),3.17-3.06(m,8H),3.02(s,1H),2.79-2.70(m,1H),2.58-2.54(m,3 H),2.30-2.19(m,3H),2.10(s,1H),1.94-1.85(m,2H),1.79(s,2H),1.74(s,2H),1.58(dd,3H),1.22(q,4H),1.09(p,2H).

[0264] The 2θ of the product was determined by X-ray powder diffraction analysis as shown in Table 12, and the product was defined as D-mandelate salt A crystal form. The X-ray powder diffraction spectrum was shown in FIG6 .

[0265] The DSC spectrum shows that the endothermic peak is 176.10℃.

[0266] TGA spectrum shows: 40℃-100℃ weight loss of 0.91%.

[0267] DVS test data showed that under normal storage conditions (i.e., 25°C, 60% RH), the sample's moisture absorption weight gain was approximately 0.833%; under accelerated test conditions (i.e., 70% RH), the moisture absorption weight gain was approximately 1.047%; and under extreme conditions (90% RH), the moisture absorption weight gain was approximately 2.245%. During the humidity fluctuations from 0% to 95% RH, the sample's desorption process overlapped with the adsorption process. XRPD patterns revealed no change in the crystal form before and after DVS testing.

[0268] Table 12

[0269] Example 9D - Preparation of Mandelate A Crystalline Form

[0270] The compound of Formula I (1.1 g, 1.38 mmol) was dissolved in 40 mL of ethyl acetate. A solution of D-mandelic acid (231.46 mg, 1.52 mmol) in ethyl acetate (5 mL) was added. The reaction mixture became clear and stirred at room temperature for 48 hours. A solid precipitated, and the reaction mixture was filtered, the filter cake collected, and vacuum dried to give the title product (1.2 g, 92.3% yield).

[0271] 1 H NMR characterization showed that the compound represented by Formula I formed a salt with D-mandelic acid in a 1:1 ratio.

[0272] H NMR(500MHz,DMSO)δ10.76(s,1H),7.60(d,1H),7.41(d,2H),7.34(t,2H),7.28(t,1H),7.18 -7.11(m,2H),7.07(t,1H),6.91(t,1H),6.81(d,1H),6.67(dd,1H),6.26(d, 1H),6.16(ddd,2H),5.62(d,1H),5.00(s,1H),4.31(ddd,1H),4.04(h,1H),3 .45(d,1H),3.39-3.33(m,3H),3.18-2.98(m,8H),2.94-2.84(m,2H),2.58(d t,1H),2.49(s,2H),2.16-2.3(m,3H),2.10(dq,1H),1.91-1.72(m,6H),1.63 -1.50 (m, 3H), 1.21 (d, 4H), 1.09 -1.05 (m, 2H). X-ray powder diffraction analysis showed that the 2θ values ​​were as shown in Table 12, indicating that the product was D-mandelate salt A crystal form.

[0273] Example 10 Preparation of D-mandelate salt crystal form A

[0274] 100 mg of the compound represented by Formula I was dissolved in a mixture of 2.5 mL of ethanol and 2.5 mL of ethyl acetate. 21 mg of solid D-mandelic acid was added and dissolved. The mixture was stirred at room temperature overnight to precipitate the product, followed by centrifugation and vacuum drying to obtain a solid. X-ray powder diffraction analysis identified the product as mandelate salt Form A. The XRPD spectrum is shown in Figure 6, and the positions of its characteristic peaks are shown in Table 12.

[0275] Example 11 Preparation of Oxalate I Crystalline Form

[0276] 100 mg of the compound represented by Formula I was added to 2 mL of acetonitrile solvent, and 24 mg of oxalic acid solid was added until insoluble. The mixture was stirred at room temperature overnight to obtain a white suspended solid, which was then centrifuged and dried in vacuo to obtain a solid. X-ray powder diffraction analysis identified the product as oxalate salt Form I. The XRPD spectrum is shown in Figure 7, and the positions of its characteristic peaks are shown in Table 13. The DSC spectrum showed an endothermic peak at 136.67°C. The TGA spectrum showed a weight loss of 2.97% from 31°C to 150°C. Ion chromatography analysis showed an oxalate ion content of 18.7%.

[0277] Table 13

[0278] Example 12 Preparation of amorphous phosphate

[0279] 100 mg of the compound represented by Formula I was added to 1 mL of acetone, followed by 10 μL of 85% phosphoric acid solution. The mixture was stirred at room temperature overnight to obtain a white suspended solid. The mixture was then centrifuged and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous phosphate salt, as shown in the XRPD spectrum in Figure 8. Ion chromatography analysis revealed a phosphate ion content of 12.51%.

[0280] Example 13 Preparation of Hydrochloride Form I

[0281] 50 mg of the compound represented by Formula I was added to 2 mL of acetonitrile solvent, followed by 11.5 μL of concentrated hydrochloric acid (36.5%). The mixture was stirred at room temperature overnight to obtain a white suspended solid, which was then centrifuged and dried under vacuum to obtain a solid. X-ray powder diffraction analysis identified the product as Form I hydrochloride. The XRPD spectrum is shown in Figure 9, and the positions of its characteristic peaks are shown in Table 14. The DSC spectrum showed an endothermic peak at 194.65°C. The TGA spectrum showed a weight loss of 9.15% from 31°C to 200°C. Ion chromatography analysis revealed a chloride ion content of 7.2%.

[0282] Table 14

[0283] Example 14 Preparation of maleate amorphous substance

[0284] 100 mg of the compound represented by Formula I was added to 2 mL of 2-methyltetrahydrofuran solvent, followed by 15 mg of solid maleic acid. The mixture was stirred at room temperature until clarified, and 8 mL of n-heptane was added. The mixture was stirred at room temperature overnight, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous maleate salt, as shown in the XRPD spectrum in Figure 10. Ion chromatography analysis revealed a maleate ion content of 12.74%.

[0285] Example 15 Preparation of Fumarate Amorphous

[0286] 10 mg of the compound represented by formula (I) was added to 0.3 mL of tetrahydrofuran solvent, followed by 1.5 mg of fumaric acid. The mixture was stirred at room temperature until clarified. 1.0 mL of n-heptane was added, the mixture was stirred at room temperature overnight, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous fumarate salt, as shown in Figure 11. Ion chromatography analysis revealed a fumarate ion content of 12.93%.

[0287] Example 16 Preparation of Hydrobromide Amorphous

[0288] 10 mg of the compound represented by Formula I was dissolved in 0.3 mL of acetone to clarify the solution. 1.5 μL of hydrobromic acid was added, and the mixture was stirred at room temperature overnight. The mixture was centrifuged and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous hydrobromide salt, as shown in the XRPD spectrum in Figure 12. Ion chromatography analysis revealed a bromide ion content of 14.91%.

[0289] Example 17 Preparation of Citrate Amorphous

[0290] 10 mg of the compound represented by formula (I) was added to 0.3 mL of tetrahydrofuran, followed by 1.5 mg of citric acid. The mixture was stirred at room temperature until clarified. 1.0 mL of n-heptane was added, the mixture was stirred at room temperature overnight, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous citrate salt, as shown in Figure 13. Ion chromatography analysis revealed a citrate ion content of 19.61%.

[0291] Example 18 Preparation of Sulfate Amorphous

[0292] 10 mg of the compound represented by Formula I was dissolved in 0.3 mL of acetonitrile to clarify. 0.70 μL of concentrated sulfuric acid was added, and the mixture was stirred at room temperature overnight. The mixture was centrifuged and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous sulfate salt, as shown in the XRPD spectrum in Figure 14. Ion chromatography analysis revealed a sulfate ion content of 15.58%.

[0293] Example 19 Preparation of amorphous methanesulfonate

[0294] 10 mg of the compound of Formula I was suspended in 0.3 mL of water. 0.85 μl of methanesulfonic acid was added. The mixture was allowed to react at room temperature for 2 hours, then stirred overnight at 40°C. The mixture was centrifuged and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed the product to be an amorphous methanesulfonate salt. The XRPD spectrum is shown in Figure 15.

[0295] Example 20 Preparation of hippurate amorphous substance

[0296] 10 mg of the compound represented by Formula I was added to 2.48 mg of solid hippuric acid and dissolved in a mixture of 0.1 mL of ethanol and 0.1 mL of ethyl acetate. 700 μL of MTBE was added to precipitate the mixture. The mixture was stirred at room temperature overnight, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous hippurate salt. The XRPD spectrum is shown in Figure 16.

[0297] Example 21 Preparation of Benzoate Amorphous

[0298] 10 mg of the compound represented by Formula I was added to 1.69 mg of solid benzoic acid and added to 0.1 mL of acetonitrile or a mixture of 0.1 mL of ethanol and 0.1 mL of ethyl acetate. 700 μL of methyl tert-butyl ether was added to precipitate the solution. The solution was stirred overnight at room temperature, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous benzoate salt. The XRPD spectrum is shown in Figure 17.

[0299] Example 22 Preparation of Benzoate Amorphous

[0300] 10 mg of the compound of Formula I was added to 1.69 mg of solid benzoic acid in 0.3 mL of methyl tert-butyl ether. The mixture was stirred overnight at room temperature, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed no distinct peaks in the XRPD spectrum, indicating that the product was an amorphous benzoate salt.

[0301] Example 23 Preparation of amorphous malate

[0302] 10 mg of the compound represented by formula (I) was added to 1.85 mg of solid malic acid and added to 0.5 mL of acetonitrile or a mixture of 0.1 mL of ethanol and 0.1 mL of ethyl acetate. 700 μL of methyl tert-butyl ether was added to precipitate the solution. The solution was stirred at room temperature overnight, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous malate salt. The XRPD spectrum is shown in Figure 18.

[0303] Example 24 Preparation of amorphous malate

[0304] 10 mg of the compound represented by formula (I) was added to 1.85 mg of solid malic acid in 0.3 mL of tetrahydrofuran. 700 μL of methyl tert-butyl ether was added to precipitate the product. The product was stirred overnight at room temperature, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed that the product was an amorphous malate salt. The XRPD spectrum is shown in Figure 18.

[0305] Example 25 Preparation of Acetate Amorphous

[0306] 10 mg of the compound represented by formula (I) was added to 11.5 μl of a 1.2 M acetic acid-ethanol solution and dissolved in 0.3 mL of acetonitrile or ethyl acetate. 700 μl of methyl tert-butyl ether was added to precipitate the solution. The solution was stirred overnight at room temperature, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed the product to be an amorphous acetate salt. The XRPD spectrum is shown in Figure 19.

[0307] Example 26 Preparation of Acetate Amorphous

[0308] 10 mg of the compound of Formula I was added to 11.5 μl of a 1.2 M acetic acid-ethanol solution, then added to 0.3 mL of methyl tert-butyl ether solution. The mixture was stirred at room temperature overnight, centrifuged, and dried under vacuum to obtain a solid. X-ray powder diffraction analysis revealed no distinct peaks in the XRPD spectrum, indicating that the product was an amorphous acetate salt.

[0309] Example 28 Amorphous Stability Study

[0310] Study on the stability of influencing factors: The free state samples were spread out in the open and the stability of the samples was investigated under high temperature (40°C, 60°C) and high humidity (RH 75%, RH 92.5%) conditions. The sampling period was 30 days.

[0311] Table 15

[0312] The experimental results of influencing factors show that the free amorphous state has good chemical stability under high temperature and high humidity.

[0313] Long-term / accelerated stability studies: Free samples were sealed in aluminum foil bags and placed under 25°C / 60% RH and 40°C / 75% RH conditions for stability testing. The results are shown below.

[0314] Table 16

[0315] The experimental results show that the free amorphous state has good physical and chemical stability when placed under long-term accelerated conditions for 6 months.

[0316] Example 29 Salt Stability Study

[0317] Study on the stability of factors affecting salt type: The salt type samples were laid out in an open position and the stability of the samples was investigated under high temperature (40°C, 60°C) and high humidity (RH 75%) conditions. The sampling period was 30 days.

[0318] Table 17

[0319] Table 18

[0320] Table 19

[0321] Salt-type long-term / accelerated stability: The samples were sealed in aluminum foil bags and placed under 25°C / 60% RH and 40°C / 75% RH conditions for stability testing. The results are shown below.

[0322] Table 20

[0323] The experimental results show that the succinate B crystal form and the mandelate A crystal form have good chemical and physical stability after being placed under long-term accelerated conditions for 6 months. The maleate amorphous form also has good chemical and physical stability after being placed under long-term conditions for 6 months.

Claims

1. An amorphous form of the compound represented by formula I.

2. The amorphous material according to claim 1, characterized in that The XRPD spectrum of the amorphous material has no sharp peaks, and preferably has non-sharp peaks.

3. A pharmaceutically acceptable salt of the compound of formula I, wherein the pharmaceutically acceptable salt is selected from succinate, mandelate, oxalate, phosphate, hydrochloride, maleate, fumarate, hydrobromide, citrate, sulfate, methanesulfonate, hippurate, benzoate, malate, acetate; preferably succinate and mandelate; more preferably succinate and D-mandelate.

4. The pharmaceutically acceptable salt of the compound of formula I according to claim 3, wherein the chemical ratio of the compound of formula I to the acid molecule or acid radical is 2:0.5 to 1:3; preferably, the chemical ratio of the compound of formula I to the acid molecule or acid radical is selected from 2:1 to 1:3; more preferably, the chemical ratio of the compound of formula I to the acid molecule or acid radical is selected from 1:0.5, 1:1, 1:1.5 or 1:

2.

5. A succinate salt of a compound of formula I, wherein: The chemical ratio of the compound of formula I to succinate or succinic acid is about 2:1 to 1:3, preferably 1:1 or 1:

2.

6. A succinate B crystal form of the compound represented by formula I, wherein the X-ray powder diffraction pattern represented by a diffraction angle of 2θ has characteristic peaks at 6.402, 9.400, 15.728, 17.957, and 19.070; preferably, characteristic peaks are present at 6.402, 9.400, 15.728, 17.957, 19.070, and 21.589; more preferably, the X-ray powder diffraction pattern represented by a diffraction angle of 2θ is as shown in Figure 3.

7. A method for preparing the crystal form according to claim 6, comprising: The compound represented by formula I is mixed with a solvent and succinic acid, and crystallized to obtain succinate B crystal form, wherein the solvent is selected from ketone solvents; preferably, the ketone solvent is acetone.

8. A D-mandelate salt of a compound of formula I, wherein: The chemical ratio of the compound of formula I to mandelate or mandelic acid is about 1:

1.

9. A D-mandelate salt A crystalline form of the compound of formula I, wherein the X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 10.554, 13.168, 15.728, 17.944, and 19.784; preferably, characteristic peaks are at 6.159, 8.371, 10.554, 13.168, 15.728, 17.944, 19.784, and 20.381; more preferably, characteristic peaks are at 6.159, 8.371, 10.554, 13.168, 15.728, 17.944, 19.784, 20.381, 21.121, and 21.434; Further preferably, the X-ray powder diffraction pattern represented by the diffraction angle 2θ is as shown in FIG6 .

10. A method for preparing the crystal form according to claim 9, comprising: The compound represented by formula I is mixed with a solvent and D-mandelic acid, and crystallized to obtain D-mandelate salt A crystal form; The solvent is selected from one or more of isopropanol, ethanol, and ethyl acetate, and preferably the solvent is selected from isopropanol / ethyl acetate, ethanol / ethyl acetate, and ethyl acetate.

11. A pharmaceutical composition comprising the amorphous substance according to any one of claims 1 to 2, the pharmaceutically acceptable salts according to claims 3 to 5 and 8, the crystal form according to any one of claims 6 and 9, or the crystal form obtained by the preparation method according to any one of claims 7 and 10, and optionally a pharmaceutically acceptable excipient.

12. A method for preparing a pharmaceutical composition according to claim 11, comprising the step of mixing the amorphous substance according to any one of claims 1 to 2, the pharmaceutically acceptable salts according to claims 3 to 5 and 8, the crystalline form according to any one of claims 6 and 9, or the crystalline form obtained by the preparation method according to any one of claims 7 and 10 with a pharmaceutically acceptable excipient.

13. Use of the amorphous substance according to any one of claims 1-2, the pharmaceutically acceptable salts according to claims 3-5 and 8, the crystalline form according to any one of claims 6 and 9, the crystalline form prepared by the preparation method according to any one of claims 7 and 10, or the pharmaceutical composition according to claim 11 in the preparation of a drug for regulating ubiquitination and degradation of androgen receptor (AR) protein.

14. Use of the amorphous substance according to any one of claims 1-2, the pharmaceutically acceptable salts according to claims 3-5 and 8, the crystalline form according to any one of claims 6 and 9, the crystalline form obtained by the preparation method according to any one of claims 7 and 10, or the pharmaceutical composition according to claim 11 in the preparation of a medicament for treating and / or preventing a disease or condition mediated or dependent on the androgen receptor; wherein the disease or condition mediated or dependent on the androgen receptor is preferably selected from tumors, male sexual dysfunction and Kennedy's disease.

15. The use according to claim 14, wherein the androgen receptor-mediated or -dependent disease or condition is selected from prostate cancer, prostate hyperplasia, hirsutism, alopecia, anorexia nervosa, breast cancer, acne, male sexual dysfunction, Kennedy's disease and AIDS, preferably prostate cancer, more preferably hormone-sensitive prostate cancer or hormone-refractory prostate cancer.

Citation Information

Patent Citations

  • Compounds and methods for the targeted degradation of androgen receptor

    WO2018071606A1

  • N / o-linked degrons and degronimers for protein degradation

    WO2018237026A1

  • Spirocyclic androgen receptor protein degraders

    WO2021055756A1

  • Chimeric compound for targeted degradation of androgen receptor protein, preparation method therefor, and medical use thereof

    WO2023093845A1

  • Spiroandrogen receptor protein degradation agent

    CN115023267A

Cited By

  • Method for treating prostate cancer

    EP4740946A4

  • Method for treating prostate cancer

    WO2026179886A1